scholarly journals The Expression And The Tumor Suppressor Role of CLDN6 In Colon Cancer

Author(s):  
Huinan Qu ◽  
Min Wang ◽  
Miaomiao Wang ◽  
Yuanyuan Liu ◽  
Chengshi Quan

Abstract As a member of the tight junction family, CLDN6 is a tumor suppressor gene in breast cancer, but its role in colon cancer is unknown. In this research, we aimed at revealing the function of CLDN6 in colon cancer. We found that CLDN6 expressed lower in colon cancer tissues compared with adjacent normal tissues and the low expression of CLDN6 was correlated with lymph node metastasis. Similarly, CLDN6 expressed lower in the colon cancer cell line SW1116 compared with the normal human colon epithelial cell line NCM460. Upon CLDN6 overexpression in SW1116 cells, the proliferation of cells was suppressed in vitro and in vivo. Consistently, the migration and invasion abilities of cells were significantly inhibited after CLDN6 overexpression. Furthermore, the TYK2/STAT3 pathway was activated in SW1116/CLDN6 cells, and inhibition of this pathway with AG490 reversed the inhibition of migration and invasion of SW1116 cells by CLDN6. Therefore, our data indicated that CLDN6 acted as a tumor suppressor and had the potential to be regarded as a biomarker for the progression of colon cancer.

2018 ◽  
Vol 9 (1) ◽  
pp. 190-199 ◽  
Author(s):  
Geet P. Asnani ◽  
Chandrakant R. Kokare

AbstractThe aim of this study was to formulate a novel dual crosslinked hydrogel bead using Portulaca mucilage for colon-targeted delivery of 5-fluorouracil (5-FU) and evaluate its safety, specificity and efficacy. The ionotropic gelation technique was employed to prepare the hydrogel beads of Portulaca mucilage. For this, the mucilage was initially crosslinked with alginate and calcium ions. Epichlorohydrin was employed as a crosslinker in the second crosslinking step. The formulation was subjected to in vitro and in vivo studies to evaluate morphology, size, cytotoxicity, and organ distribution. Human HT-29 colon cancer cell-line was used for in vitro assays and in vivo studies were performed in Wistar rats to assess the usefulness and effectiveness of the formulation for colon cancer therapy. Microsphere sizes ranged from 930 to 977μm and possessed a high level of drug encapsulation efficiency (ca. 78% w/w). Compared with 5-FU solution (Tmax = 1.2 h, mean resident time: MRT = 3.3h) the dual crosslinked Portulaca microspheres exhibited sustained drug release after oral administration to rats (Tmax = 16h, MRT = 14h). The relative bioavailability of 5-FU solution and the microspheres were 100 and 93.6% respectively. Tissue distribution studies indicated high concentration of 5-FU in colon. In-vitro anticancer assay demonstrated IC50 value of 11.50 μg/ml against HT-29 colon cancer cell line. The epichlorohydrin cross-linked Portulaca microspheres prepared in this study provided sustained release of 5-FU up to 16h in the colonic region and enhanced the antitumor activity of the neoplastic drug. The formulation is hence an ideal carrier system for colon-targeted drug delivery.


2010 ◽  
Vol 128 (9) ◽  
pp. 2038-2049 ◽  
Author(s):  
Yan Ning ◽  
Philipp C. Manegold ◽  
Young Kwon Hong ◽  
Wu Zhang ◽  
Alexandra Pohl ◽  
...  

2016 ◽  
Vol 45 (6) ◽  
pp. 2462-2475 ◽  
Author(s):  
Elena García-Moreno ◽  
Alejandro Tomás ◽  
Elena Atrián-Blasco ◽  
Sonia Gascón ◽  
Eduardo Romanos ◽  
...  

Alkyne gold(i) derivatives with the water soluble phosphanes PTA and DAPTA were described and their anticancer potential against the colon cancer cell line Caco-2 (PD7 and TC7 clones) was studied.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Xiaocui Bian ◽  
Fang Cao ◽  
Xiaowan Wang ◽  
Yuhong Hou ◽  
Haitao Zhao ◽  
...  

AbstractColorectal cancer (CRC) is one of the most common and fatal gastrointestinal cancers worldwide. Considering their diversity, the establishment of new continuous CRC cell lines with clear genetic backgrounds will provide useful tools for exploring molecular mechanisms, screening and evaluating antitumor drugs in CRC studies. Our de novo CRC cell line, PUMC-CRC1 (Peking Union Medical College Colorectal Cancer 1) was derived from a 47-year-old Chinese female patient diagnosed with moderately to poorly differentiated colon adenocarcinoma. Multiple experiments were used for full characterization. The new cell line was epithelial-like and was passaged for more than 40 times, with a population doubling time of 44 h in vitro, detected by cell counts. The cells exhibited complicated chromosomal abnormalities. The tumor formation rate in SCID mice was 100%. The xenograft tumor was adenocarcinoma with poor to moderate differentiation by Haematoxylin and Eosin staining (H&E) sections. Immunohistochemistry (IHC) analysis and next-generation sequencing (NGS) revealed microsatellite stable (MSS), APC (p.T1493fs) inactivation, KRAS (p.G12V) activation, and SMAD4 (p.V506A) mutation. Quality control of the cell line proved mycoplasma negative and identical STR profile with that of the original tissue, and no interspecific or intraspecific cross contamination was detected. In conclusion, PUMC-CRC1 was a newly established and well characterized human colon cancer cell line, which might be a good model for both in vitro and in vivo studies of the mechanism of colon cancer progression and the treatment strategies for MSS CRC.


Sign in / Sign up

Export Citation Format

Share Document